

# MULTIPLE SCLEROSIS REFERRAL FORM A-C



Patient Information

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_ Sex:  M  F  
 Phone: \_\_\_\_\_ Cell Phone: \_\_\_\_\_ Email Address: \_\_\_\_\_  
 Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_  
 ICD-10 Diagnosis Code: \_\_\_\_\_ Diagnosis: \_\_\_\_\_  
 Allergies (please note reaction): \_\_\_\_\_  Latex  
 Current Medications: (list here or attach a medication list): \_\_\_\_\_  
 Comorbidities: (list here or attach a list): \_\_\_\_\_

## INSURANCE INFORMATION - FAX COPY OF PATIENT'S INSURANCE CARD - BOTH SIDES

Prescription Information

MEDICATION	STRENGTH	DIRECTIONS	QUANTITY	REFILLS
<input type="checkbox"/> Avonex (interferon beta-1a)	<input type="checkbox"/> AvoStartGrip Titration Kit <input type="checkbox"/> 30mcg Pen <input type="checkbox"/> 30mcg Prefilled Syringe <input type="checkbox"/> 30mcg Single Dose Vial	<input type="checkbox"/> Loading dose: Inject 7.5mcg IM once weekly for one week. Then inject 15mcg IM once weekly for week 2. Then inject 22.5mcg IM once weekly for week 3. Then inject 30mcg IM once weekly and thereafter. <input type="checkbox"/> Inject 30mcg intramuscularly once a week.	<input type="checkbox"/> 1 titration kit (3 syringes) <input type="checkbox"/> 4 syringes/vials/pens <input type="checkbox"/> ___syringes/vials/pens	
<input type="checkbox"/> Betaseron (interferon beta-1b)	0.3 mg Kit (contains 14 vials)	<input type="checkbox"/> Loading Dose: Inject 0.0625mg (0.25mL) subcutaneously every other day for weeks 1 and 2, then inject 0.125mg (0.5mL) every other day for weeks 3 and 4, then inject 0.1875mg (0.75mL) every other day for weeks 5 and 6, then inject 0.25mg (1mL) every other day for week 7 and thereafter.	28 vials	
		<input type="checkbox"/> Maintenance Dose: Inject 0.25mg (1mL) subcutaneously every other day.	14 vials	
		<input type="checkbox"/> Other:		
<input type="checkbox"/> Copaxone (glatiramer acetate)	<input type="checkbox"/> 20mg/mL Prefilled Syringe (1 kit = 30 syringes)	Inject 20mg subcutaneously once daily.	30 syringes	
	<input type="checkbox"/> 40mg/mL Prefilled Syringe (1 kit = 12 syringes)	Inject 40mg subcutaneously 3 times per week, at least 48 hours apart.	12 syringes	

Treatment History:  New to Therapy  Continuation of Therapy

Is patient pregnant, nursing or planning pregnancy?  Yes  No  N/A

Is patient using prescribed therapy in combination with other biologics for MS?  Yes  No

Prescriber Information

Prescriber Name: \_\_\_\_\_  
 State License #: \_\_\_\_\_ DEA #: \_\_\_\_\_ NPI: \_\_\_\_\_  
 Additional Contact Person Name: \_\_\_\_\_  
 Group or Hospital: \_\_\_\_\_ Phone: \_\_\_\_\_  
 Fax: \_\_\_\_\_ Email Address: \_\_\_\_\_  
 Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_

Prescriber Signature: \_\_\_\_\_  
 Product Substitution Permitted \_\_\_\_\_ Dispensed as Written \_\_\_\_\_ Date \_\_\_\_\_

The prescriber is to comply with state specific prescription requirements such as e-prescribing, state specific prescription form, fax language, etc. Non-compliance with state specific requirements could result in outreach to the prescriber.

Delivery Information

Ship to Patient  Ship to Prescriber/Clinic  Pick up at Albertsons Companies Pharmacy Date Medication Needed: \_\_\_\_\_

Confidentiality Warning: The information contained in this facsimile message is privileged and confidential information intended only for the review and use of the individual or entity to which it is addressed. If the reader of this message is not the intended recipient, you are hereby notified that any disclosure, dissemination, distribution or copying of this communication of the information contained herein is strictly prohibited. If you have received this communication in error, please immediately notify sender by telephone, and destroy the original documents.

It's as simple as caring.

# MULTIPLE SCLEROSIS REFERRAL FORM D-G



**Patient Information**

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_ Sex:  M  F  
 Phone: \_\_\_\_\_ Cell Phone: \_\_\_\_\_ Email Address: \_\_\_\_\_  
 Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_  
 ICD-10 Diagnosis Code: \_\_\_\_\_ Diagnosis: \_\_\_\_\_  
 Allergies (please note reaction): \_\_\_\_\_  Latex  
 Current Medications: (list here or attach a medication list): \_\_\_\_\_  
 Comorbidities: (list here or attach a list): \_\_\_\_\_

## INSURANCE INFORMATION - FAX COPY OF PATIENT'S INSURANCE CARD - BOTH SIDES

**Prescription Information**

MEDICATION	STRENGTH	DIRECTIONS	QUANTITY	REFILLS
<input type="checkbox"/> Extavia (interferon beta-1b)	0.3mg Kit (contains 15 vials)	<input type="checkbox"/> Loading Dose: Inject 0.0625mg (0.25mL) subcutaneously every other day for weeks 1 and 2, then inject 0.125mg (0.5mL) every other day for weeks 3 and 4, then inject 0.1875mg (0.75mL) every other day for weeks 5 and 6, then inject 0.25mg (1mL) every other day for week 7 and thereafter.	30 vials	
		<input type="checkbox"/> Maintenance Dose: Inject 0.25mg (1mL) subcutaneously every other day.	15 vials	
		<input type="checkbox"/> Other:		
<input type="checkbox"/> Gilenya (fingolimod)	0.5mg Capsule	Take 1 capsule by mouth once daily.	30 capsules	
<input type="checkbox"/> Glatopa (glatiramer acetate)	<input type="checkbox"/> 20mg/mL Prefilled Syringe (1 kit = 30 syringes)	Inject 20mg subcutaneously once daily.	30 syringes	
	<input type="checkbox"/> 40mg/mL Prefilled Syringe (1 kit = 12 syringes)	Inject 40mg subcutaneously 3 times per week, at least 48 hours apart.	12 syringes	
<input type="checkbox"/> Novantrone (mitoxantrone)	<input type="checkbox"/> 20mg/10mL (10mL) Concentrate	<input type="checkbox"/> Dilute and administer 12mg/m <sup>2</sup> via intravenous infusion (over 5 to 15 minutes every 3 months. Body surface area _____ m <sup>2</sup> (or m squared))	_____ vials	
	<input type="checkbox"/> 25mg/12.5mL (12.5mL) Concentrate			
	<input type="checkbox"/> 30mg/15mL (15mL) Concentrate			

**Treatment History:**  New to Therapy  Continuation of Therapy

Is patient pregnant, nursing or planning pregnancy?  Yes  No  N/A  
 Is patient using prescribed therapy in combination with other biologics for MS?  Yes  No  
 Novantrone: Is patient's LVEF less than 50%?  Yes  No  
 Patient's lifetime (cumulative) Novantrone dose: \_\_\_\_\_ mg/m<sup>2</sup>  
 Please attach the latest copy of CBC with differential.

**Prescriber Information**

Prescriber Name: \_\_\_\_\_  
 State License #: \_\_\_\_\_ DEA #: \_\_\_\_\_ NPI: \_\_\_\_\_  
 Additional Contact Person Name: \_\_\_\_\_  
 Group or Hospital: \_\_\_\_\_ Phone: \_\_\_\_\_  
 Fax: \_\_\_\_\_ Email Address: \_\_\_\_\_  
 Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_

Prescriber Signature: \_\_\_\_\_  
 Product Substitution Permitted \_\_\_\_\_ Dispensed as Written \_\_\_\_\_ Date \_\_\_\_\_

The prescriber is to comply with state specific prescription requirements such as e-prescribing, state specific prescription form, fax language, etc. Non-compliance with state specific requirements could result in outreach to the prescriber.

**Delivery Information**

Ship to Patient  Ship to Prescriber/Clinic  Pick up at Albertsons Companies Pharmacy Date Medication Needed: \_\_\_\_\_

*Confidentiality Warning: The information contained in this facsimile message is privileged and confidential information intended only for the review and use of the individual or entity to which it is addressed. If the reader of this message is not the intended recipient, you are hereby notified that any disclosure, dissemination, distribution or copying of this communication of the information contained herein is strictly prohibited. If you have received this communication in error, please immediately notify sender by telephone, and destroy the original documents.*

It's as simple as caring.

# MULTIPLE SCLEROSIS REFERRAL FORM H-R



Patient Information

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_ Sex:  M  F  
 Phone: \_\_\_\_\_ Cell Phone: \_\_\_\_\_ Email Address: \_\_\_\_\_  
 Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_  
 ICD-10 Diagnosis Code: \_\_\_\_\_ Diagnosis: \_\_\_\_\_  
 Allergies (please note reaction): \_\_\_\_\_  Latex  
 Current Medications: (list here or attach a medication list): \_\_\_\_\_  
 Comorbidities: (list here or attach a list): \_\_\_\_\_

## INSURANCE INFORMATION - FAX COPY OF PATIENT'S INSURANCE CARD - BOTH SIDES

Prescription Information

MEDICATION	STRENGTH	DIRECTIONS	QUANTITY	REFILLS
<input type="checkbox"/> Rebif (interferon beta-1a)	<input type="checkbox"/> Titration Pack (six 8.8mcg and six 22mcg prefilled syringes)	<input type="checkbox"/> Loading Dose (44mcg target): Inject 8.8mcg subcutaneously three times weekly for weeks 1 and 2, then inject 22mcg three times weekly for weeks 3 and 4, then inject 44mcg three times weekly thereafter. Doses should be separated by at least 48 hours. <input type="checkbox"/> Loading Dose (22mcg target): Inject 4.4mcg subcutaneously three times weekly for weeks 1 and 2, then inject 11mcg three times weekly for weeks 3 and 4, then inject 22mcg three times weekly thereafter. Doses should be separated by at least 48 hours.	12 syringes	
	<input type="checkbox"/> 44mcg/0.5mL Prefilled Syringe <input type="checkbox"/> 22mcg/0.5mL Prefilled Syringe	<input type="checkbox"/> Maintenance Dose: Inject 44mcg subcutaneously three times weekly. Doses should be separated by at least 48 hours. <input type="checkbox"/> Maintenance Dose: Inject 22mcg subcutaneously three times weekly. Doses should be separated by at least 48 hours. <input type="checkbox"/> Other:	12 syringes	
<input type="checkbox"/> Rebif Rebidose (interferon beta-1a)	<input type="checkbox"/> Titration Pack (six 8.8mcg and six 22mcg autoinjectors) *for 44mcg target dose only*	<input type="checkbox"/> Loading Dose (44mcg target): Inject 8.8mcg subcutaneously three times weekly for weeks 1 and 2, then inject 22mcg three times weekly for weeks 3 and 4, then inject 44mcg three times weekly thereafter. Doses should be separated by at least 48 hours.	12 syringes	
	<input type="checkbox"/> 44mcg/0.5mL Autoinjector <input type="checkbox"/> 22mcg/0.5mL Autoinjector	<input type="checkbox"/> Maintenance Dose: Inject 44mcg subcutaneously three times weekly. Doses should be separated by at least 48 hours. <input type="checkbox"/> Maintenance Dose: Inject 22mcg subcutaneously three times weekly. Doses should be separated by at least 48 hours. <input type="checkbox"/> Other:	12 syringes/ autoinjectors	

Treatment History:  New to Therapy  Continuation of Therapy

Is patient pregnant, nursing or planning pregnancy?  Yes  No  N/A  
 Is patient using prescribed therapy in combination with other biologics for MS?  Yes  No

Prescriber Information

Prescriber Name: \_\_\_\_\_  
 State License #: \_\_\_\_\_ DEA #: \_\_\_\_\_ NPI: \_\_\_\_\_  
 Additional Contact Person Name: \_\_\_\_\_  
 Group or Hospital: \_\_\_\_\_ Phone: \_\_\_\_\_  
 Fax: \_\_\_\_\_ Email Address: \_\_\_\_\_  
 Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_

Prescriber Signature: \_\_\_\_\_  
 Product Substitution Permitted \_\_\_\_\_ Dispensed as Written \_\_\_\_\_ Date \_\_\_\_\_

The prescriber is to comply with state specific prescription requirements such as e-prescribing, state specific prescription form, fax language, etc. Non-compliance with state specific requirements could result in outreach to the prescriber.

Delivery Information

Ship to Patient  Ship to Prescriber/Clinic  Pick up at Albertsons Companies Pharmacy Date Medication Needed: \_\_\_\_\_

Confidentiality Warning: The information contained in this facsimile message is privileged and confidential information intended only for the review and use of the individual or entity to which it is addressed. If the reader of this message is not the intended recipient, you are hereby notified that any disclosure, dissemination, distribution or copying of this communication of the information contained herein is strictly prohibited. If you have received this communication in error, please immediately notify sender by telephone, and destroy the original documents.

It's as simple as caring.

# MULTIPLE SCLEROSIS REFERRAL FORM S-Z



Patient Information

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_ Sex:  M  F  
 Phone: \_\_\_\_\_ Cell Phone: \_\_\_\_\_ Email Address: \_\_\_\_\_  
 Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_  
 ICD-10 Diagnosis Code: \_\_\_\_\_ Diagnosis: \_\_\_\_\_  
 Allergies (please note reaction): \_\_\_\_\_  Latex  
 Current Medications: (list here or attach a medication list): \_\_\_\_\_  
 Comorbidities: (list here or attach a list): \_\_\_\_\_

## INSURANCE INFORMATION - FAX COPY OF PATIENT'S INSURANCE CARD - BOTH SIDES

Prescription Information

MEDICATION	STRENGTH	DIRECTIONS	QUANTITY	REFILLS
<input type="checkbox"/> Tysabri (natalizumab)	300mg/15mL Concentrate	Administer 300mg via intravenous infusion over 1 hour every 4 weeks.	<input type="checkbox"/> 1 vial <input type="checkbox"/> ____ vials	
Other Medication Name:				

**Treatment History:**  New to Therapy  Continuation of Therapy

Is patient pregnant, nursing or planning pregnancy?  Yes  No  N/A

Is patient using prescribed therapy in combination with other biologics for MS?  Yes  No

Prescriber Information

Prescriber Name: \_\_\_\_\_  
 State License #: \_\_\_\_\_ DEA #: \_\_\_\_\_ NPI: \_\_\_\_\_  
 Additional Contact Person Name: \_\_\_\_\_  
 Group or Hospital: \_\_\_\_\_ Phone: \_\_\_\_\_  
 Fax: \_\_\_\_\_ Email Address: \_\_\_\_\_  
 Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_

Prescriber Signature: \_\_\_\_\_  
 Product Substitution Permitted \_\_\_\_\_ Dispensed as Written \_\_\_\_\_ Date \_\_\_\_\_

The prescriber is to comply with state specific prescription requirements such as e-prescribing, state specific prescription form, fax language, etc. Non-compliance with state specific requirements could result in outreach to the prescriber.

Delivery Information

Ship to Patient  Ship to Prescriber/Clinic  Pick up at Albertsons Companies Pharmacy Date Medication Needed: \_\_\_\_\_

*Confidentiality Warning: The information contained in this facsimile message is privileged and confidential information intended only for the review and use of the individual or entity to which it is addressed. If the reader of this message is not the intended recipient, you are hereby notified that any disclosure, dissemination, distribution or copying of this communication of the information contained herein is strictly prohibited. If you have received this communication in error, please immediately notify sender by telephone, and destroy the original documents.*

It's as simple as caring.